The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

(2013) A. Romer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival of Patients With Pancreatic Neuroendocrine Tumors

(2013) Ilaria Marinoni et al.   GASTROENTEROLOGY

Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor Targeting

(2012) Meike Körner et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

(2012) Linda Villard et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

(2011) Jolanta Kunikowska et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors

(2011) Hee Sung Kim et al.   Cancer Research and Treatment

[90Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer

(2009) Fabienne Iten et al.   CANCER

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

(2008) Amani Asnacios et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY